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In This IssuePredicting Radiation Esophagitis Using 18F-FDG PET Dur-
ing Chemoradiotherapy for Locally Advanced Non–Small
Cell Lung Cancer
The study evaluated changes in esophageal 18F-ﬂuoro-
deoxyglucose (FDG) uptake during chemoradiotherapy
(CRT) and its association with the onset and severity of
radiation esophagitis (RE) in the treatment of patients
with stage II-III non–small cell lung cancer (NSCLC).
Serial four-dimensional computed tomography and PET
scans were used during CRT (60-74Gy). The volume of
esophagus receiving 50 Gy (V50) and volume of esophagus
receiving 60 Gy (V60) were associated with the develop-
ment of RE. Of the 27 patients analyzed, 74% developed RE,
of which 22% were grade 3. Patients with RE showed
signiﬁcant increase in SUVpeak (esophagus peak standard
uptake value) at week 4 (p¼0.01) and week 7 (p¼0.03); the
signiﬁcant increase was at week 2 (p¼0.01) and week 7
(p¼0.03) for grade 3 RE vs. < grade 3 RE. Patients with RE
had signiﬁcantly greater median V50 and V60 (46.3% and
33.4%, respectively). The C-statistic (area under the curve
[AUC]) indicated that percentage change in SUVpeak at week
2, V50 and V60 could be of predictive values for grade 3 RE (AUC¼0.69, 0.67 and 0.66, respectively). Taken together, the
ﬁndings from serial FDG-PET images during CRT demonstrated signiﬁcant increases in SUVpeak for patients with RE, with
changes at week 2 predictive of those at risk for developing grade 3 RE. This could guide adaptive planning and early
intervention. (p. 213)Image source: Food and Drug Administration
(http://www.fda.gov)Nodal Upstaging Is More Common with Thoracotomy than
with VATS During Lobectomy for Early-Stage Lung Cancer:
An Analysis from the National Cancer Data Base
The authors sought to investigate the differences in nodal
evaluation and upstaging between thoracotomy (open)
and video-assisted thoracic surgery (VATS) lobectomy for
early-stage lung cancer, which could be a signiﬁcant
barrier to widespread use of VATS. The analysis of 16,983
lobectomies in patients with T2N0M0 or lower lung
cancer from the National Cancer Data Base showed that
VATS accounted for 29.1%. Higher frequency of nodal upstaging was observed in the open group (12.8% vs.
10.3%; p<0.001). The same observation was found in the 4,437 matched pairs, and in a subgroup of patients
with 7 lymph nodes examined (14.0% vs. 12.1%; p¼0.03). But there was no signiﬁcant difference in nodal
upstaging between the open and VATS groups for patients treated in an academic/research facility (12.2% vs.
10.5%, p¼0.08). In summary, nodal upstaging for early-stage lung cancer was more common with thoracotomy
than VATS, and seems to be inﬂuenced by facility type. Further studies are required to assess differences in
long-term survival rates between thoracotomy and VATS in this patient population. Nodal staging with stan-
dardized quality assurance in VATS is needed to eliminate the differences in staging compared with the open
approach. (p. 222)Journal of Thoracic Oncology Vol. 11 No. 2: 131-138
132 Journal of Thoracic Oncology Vol. 11 No. 2Multiplex Diagnosis of Oncogenic
Fusion and MET Exon Skipping
by Molecular Counting Using
Formalin-FixedParafﬁnEmbedded
Lung Adenocarcinoma Tissues
This study describes the use of a
multiplex assay in detecting aber-
rant transcripts, resulting from fu-
sions of the anaplastic lymphoma
receptor tyrosine kinase gene
(ALK), ret proto-oncogene (RET),
ROS proto-oncogene 1, receptor
tyrosine kinase gene (ROS1), BRaf
proto-oncogene, serine/threonine
kinase gene (BRAF), and neuregulin
1 gene (NRG1) and intronic MMNG
HOS Transforming gene (MET)
mutations, which are rare and mutually exclusive in lung adenocarcinoma. A molecular counting (MC) assay,
which quantiﬁes RNA molecules by simultaneous hybridization of several probes, was used to assess 36 aberrant
transcripts in 41 resected lung adenocarcinoma tissues harboring one of these transcripts as determined by whole
transcriptome sequencing (test cohort) or reverse transcription polymerase chain reaction (validation cohort). Frozen
and formalin-ﬁxed parafﬁn-embedded samples from the test cohort (n¼22) were analyzed to determine diagnostic
threshold values of each of the 36 transcripts. The MC assay detected oncogenic transcript levels based on these
thresholds with 100% accuracy in the validation cohort (n¼19). Oncogenic fusions were also accurately detected
in bronchial lavage ﬂuid and transbronchial biopsy samples. In summary, this MC assay allows simultaneous detection
of multiple druggable oncongenic fusion and exon-skipped transcripts in FFPE lung tumor samples with high accuracy
and robustness. (p. 203)Screening with Low-Dose
Computed Tomography Does
Not Improve Survival of Small
Cell Lung Cancer
The authors retrospectively
reviewed data from two lung
cancer screening trials with low-dose computed tomography (LDCT) in Milan to evaluate the outcome of small cell
lung cancer (SCLC) in these trials and compare the incidence of SCLC in the study cohort to that in major lung cancer
screening trials. Participants diagnosed with SCLC were selected and their demographics and clinical parameters
were collected. The analysis showed 10 cases of SCLC in 45,141 person-years (22 in 100,000 person-years), which
reﬂects 6% of all lung cancer cases. The SCLC group had a cumulative tobacco consumption of 82 pack-years versus
39 pack-years in the overall study population and 46 pack-years in those with non-SCLC. Advanced stage diseases
accounted for most of the cancer cases analyzed: 7 stage IV and 1 for each of stages IIIb, IIIa, and Ia. Lobectomy was
given to 2 subjects for curative purposes, who died of diffuse metastasis within 2 years of diagnosis. The LDCT arm
achieved a median overall survival of 20.6 months, with no survivors at 3 years. Taken together, although the study
involved a small number of SCLC cases, the ﬁndings suggest that the frequency of SCLC in this study cohort was
lower than that in other screening populations with higher cumulative tobacco consumption. LDCT screening for
lung cancer did not improve survival of SCLC, in which surgery was inefﬁcient even in stage Ia SCLC and no patients
were alive at 3 years. (p. 187)
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PrevalenceandPredictors of InappropriateDeliveryofPalliativeThoracicRadiotherapy forMetastatic LungCancer
The analysis involved 46,803 patients from the National Cancer Database (2004-2012), who had stage IV lung cancer
and received palliative chest radiation therapy. Predictors of standard and nonstandard regimens (>15 fractions or
concurrent chemoradiation, CRT) were determined. Radiotherapy with >15 fractions were found in 49% of patients,
and 28% had > 25 fractions. CRT was given to approximately 19%. Long-course radiotherapy was most strongly
associated with private insurance versus uninsured (odd ratio [OR] ¼ 1.40), and treatment in community cancer
programs versus academic research programs (OR ¼ 1.49). Similar association was observed between concurrent
chemoradiotherapy and private insurance (OR ¼ 1.38) as well as community cancer programs (OR ¼ 1.44). The data
demonstrated approximately half of the study patient population with metastatic lung cancer requiring palliative
thoracic radiotherapy were over-treated, inconsistent with evidence-based guidelines, and increases the risk of
toxicity without offering a survival advantage. The strongest independent predictors of overtreatment are patients
with private insurance and treatment in community cancer centers. The authors emphasized the importance of early
involvement with palliative care and urged adherence to evidence-based treatment options in the noncurative
setting.
Koshy M, Malik R, Mahmood U, Husain Z, Weichselbaum RR, Sher DJ. Prevalence and predictors of inappropriate
delivery of palliative thoracic radiotherapy for metastatic lung cancer. J Nat Cancer Inst. 2015;107, http://dx.doi.
org/10.1093/jnci/djv278.
Alectinib in Crizotinib-Refractory ALK-Rearranged Non–Small Cell Lung Cancer: A Phase II Global Study
This study assessed the efﬁcacy and safety of alectinib, a selective ALK with good CNS penetration, in 138 patients
with crizotinib-refractory ALK-positive non–small cell lung cancer (NSCLC), of which 84 patients had CNS metastases
at baseline and 122 were response evaluable. An objective response rate (ORR) of 50%, with a median duration of
response (DOR) of 11.2 months was observed in these patients; an ORR of 45% was achieved in 96 patients with
prior chemotherapy. The overall study population achieved a median progression-free survival of 8.9 months, CNS
disease control rate of 83%, and a median CNS DOR of 10.3 months. Patients with baseline measurable CNS lesions
(n¼35) had a CNS ORR of 57%. Complete CNS response was found in 43% of the 23 patients with baseline CNS
measurable or nonmeasurable metastases with no prior radiation. Cumulative CNS progression rate at 12 months
was lower than the cumulative non-CNS progression rate in the overall study population (24.8% vs. 33.2%). Con-
stipation (33%), fatigue (26%), and peripheral edema (25%) were the common adverse events, mostly grade 1 to 2.
The results suggest that alectinib is highly active, with well-tolerated safety proﬁle for the treatment of advanced,
crizotinib-refractory ALK-positive NSCLC, including those with CNS metastases.
Ou SI, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-rearranged non–small-cell lung cancer: a phase
II global study [e-pub ahead of print]. J Clin Oncol. http://dx.doi.org/10.1200/jco.2015.63.9443, accessed December
14, 2015.
Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
The study investigated the effect of intratumoral heterogeneity on genetic and histologic characteristics of ALK-
rearranged adenocarcinoma (LADC) by assessing ALK fusions and EGFR mutations in 629 patients with LADC using
laser-capture microdissection. ALK fusions were found in 4.8% of the patients, EGFRmutations were found in 57.9%,
and coexistence of ALK fusions and EGFR mutations were found in 2 patients. Nine patients had intratumoral het-
erogeneity of ALK fusions. Genetic intratumoral heterogeneity was found both between different growth patterns
and within the same growth pattern in patients with ALK/EGFR co-alteration. The analysis of 629 patients indicated
that ALK fusions appeared to be more common in acinar-predominant LADCs. However, ALK fusions were positively
correlated with a micropapillary pattern (P ¼ 0.002) while negatively correlated with a lepidic pattern (P ¼ 0.008) in
an expanded statistical analysis of 900 individual adenocarcinoma components. In summary, the ﬁndings demon-
strated high intratumoral heterogeneity of molecular and histopathologic features in both single-driver and ALK/
EGFR co-altered LADCs. Altered molecular oncogenic drivers in spatially separated subclones of the same tumor
134 Journal of Thoracic Oncology Vol. 11 No. 2could be different, adversely affecting accurate diagnosis and optimal treatment decisions. Further studies are
warranted to understand the underlying mechanisms.
Cai W, Lin D, Wu C, et al. Intratumoral heterogeneity of ALK-rearranged and ALK/EGFR coaltered lung adenocar-
cinoma. J Clin Oncol. 2015;33:3701-3709.
Comparing Patient-Derived Xenograft and Computational Response Prediction for Targeted Therapy in
Patients of Early-Stage Large Cell Lung Cancer
The authors analyzed cancer samples from 25 patients with non–small cell lung cancer (NSCLC) to compare patient-
derived xenografts (PDX) and in silico molecular signaling map (MSM) approach in predicting response from tar-
geted therapy. A treatment response was deﬁned as tumor shrinkage of >40% after treatment of PDXs with
cetuximab and erlotinib. MSM utilized RNA-seq data from each tumor sample to predict tumor response. The results
demonstrated that cetuximab treatment led to a response of 40% from PDX and 48% from MSM predicted response
while erlotinib treatment led to 20% from PDX and 40% from MSM predicted response. Strong correlation was
established between response prediction from PDX and that from MSM under both cetuximab (84%, p¼0.001) and
erlotinib (80%, p¼0.003) treatments. Cetuximab treatment achieved a clinical response similar to predictions from
both models in 5 of 25 patients. In summary, the study suggests considerable agreement in response prediction from
MSM and PDX models, with MSM conserving time and lab resource. Further studies are required to conﬁrm the
potential of MSM-based method in guiding clinical decisions on targeted therapies.
Li J, Ye C, Mansmann UR. Comparing patient-derived xenograft and computational response prediction for targeted
therapy in patients of early-stage large cell lung cancer [e-pub ahead of print]. Clin Cancer Res. http://dx.doi.org/
10.1158/1078-0432.ccr-15-2401, accessed December 14, 2015.
Smoking Cessation and Electronic Cigarette Use Among Head and Neck Cancer Patients
The authors conducted a cross-sectional study to assess electronic cigarette (e-cig) use in head and neck (HN) cancer
patients, its impact on smoking cessation, and the different aspects of smoking cessation, including quit methods,
success, motivations, and barriers. The survey included 106 eligible patients, of whom 65% quit smoking suc-
cessfully. No difference was observed in age of ﬁrst tobacco use and in hazardous drinking between the smoking and
cessation groups (P ¼ 0.14 and 0.075, respectively). The most common method used was “cold turkey” (abruptly
stopping without smoking cessation aids, n ¼ 88, 83%), which was also the most successful (n ¼ 65, 94%). No
signiﬁcant difference was found in age, sex, race, drinking, or socioeconomic status between e-cig users and non-
users. Higher quit rates were observed in nonusers versus e-cig users (72% vs 39%; P ¼ 0.0057). Number of
cigarettes smoked did not differ signiﬁcantly between e-cig users and nonusers (463 cigarettes/month vs. 341
cigarettes/month; P ¼ 0.2). A nicotine patch was worn by 70% of e-cig users. In summary, the ﬁndings indicate that
there is desire in smoking cessation for HN cancer patients, and that e-cig did not decrease tobacco use, and is
associated with reduced likelihood of smoking cessation.
McQueen N, Partington EJ, Harrington KF, Rosenthal EL, Carroll WR, Schmalbach CE. Smoking cessation and elec-
tronic cigarette use among head and neck cancer patients [e-pub ahead of print]. Otolaryngol Head Neck Surg. http://
dx.doi.org/10.1177/0194599815613279, accessed December 14, 2015.
Prevalence of Tobacco Use among Adults in South Africa: Results from the First South African National Health
and Nutrition Examination Survey
The South African National Health and Nutrition Examination Survey conducted in 2012 in 10,000 households was
aimed to estimate the prevalence of tobacco use in South African adults stratiﬁed by demographic variables, and
determine the factors affecting smoking cessation among current smokers. Current smokers accounted for 17.6%
surveyed, with a 4-times higher prevalence in males (29.3%) versus females (7.3%) (odds ratio 5.20; p<0.001).
Western Cape had the highest current tobacco smoking prevalence (32.9%), followed by Northern Cape (31.2%), and
Free State (27.4%). Among current tobacco smokers, 29.3% received advice to quit smoking from a healthcare pro-
vider, 81.4% had noticed health warnings on tobacco packages, and 49.9% reported that warning labels had led them
February 2016 In This Issue 135to consider quitting. In summary, the study demonstrated that a large number of adult South Africans continue to use
tobacco in spite of considerable progress made in cutting tobacco use over the past 2 decades. Continuous monitoring
of tobacco use and its determinants is required to maintain the effectiveness of tobacco control strategies.
Reddy P, Zuma K, Shisana O, Kim J, Sewpaul R. Prevalence of tobacco use among adults in South Africa: Results from
the ﬁrst South African National Health and Nutrition Examination Survey. S Afr Med J. 2015;105:648-655.
News-in-BriefImage source: Food and Drug Administration (http://www.fda.gov)FDA Approves Osimertinib for EGFR T790M-
Positive NSCLC
Osimertinib (Tagrisso, AZD9291) has been
granted accelerated approval by the FDA for
the treatment of patients with advanced EGFR
T790M mutation-positive non–small cell lung
cancer (NSCLC) who progressed on prior
EGFR TKI therapy. The approval was based on
the ﬁndings from two single-arm studies. Pa-
tients with EGFR T790M-mutant NSCLC
treated with osimertinib demonstrated an
objective response rate (ORR) of 61% in the AURA trial (n¼201), and an ORR of 57%, with 2 complete responses,
6-week stable disease rate of 21%, disease control rate of 92%, and median progression-free survival of 8.6
months in the AURA2 trial (n¼210). The cobas EGFR Mutation Test v2 has also been approved as a companion
diagnostic test along with the osimertinib approval to detect the EGFR resistance mutation type that osimertinib
targets.Image source: The website of the National Cancer Institute
(http://www.cancer.gov)2015 AACR-NCI-EORTC International Conference on
Molecular Targets and Cancer Therapeutics: Tivan-
tinib in Combination with Erlotinib versus Erlotinib
Alone for EGFR Mutant NSCLC: Subgroup Results
from the Phase 3 MARQUEE Study (Abstract B194)
This was an exploratory analysis in the phase III
MARQUEE trial aimed to compare the efﬁcacy and
safety of the combination of tivantinib and erlotinib
with erlotinib alone in EGFR-mutant NSCLC patients
(n¼109), without prior EGFR and MET inhibitor
therapy but were pretreated with platinum-
doublet. Tivantinib signiﬁcantly improved
progression-free survival (PFS) of this population:
median PFS of 13.0 months in the combination arm
vs. 7.5 months in the erlotinib only arm (hazard
ratio [HR] 0.49; p¼0.0016). The median overall
survival (OS) and overall response rate (ORR) were
also increased with the addition of tivantinib,
although not statistically signiﬁcant: 25.5 vs. 20.0 months (HR¼0.68; p¼0.10), and 61% vs. 43%, respectively. At
data cut-off, 6 of the 56 patients in the combination arm remained on study treatment. No difference in common
adverse events between arms, which included diarrhea, rash and asthenia/fatigue. Higher frequency of neu-
tropenia and febrile neutropenia were expected in the tivantinib arm. The preliminary ﬁndings suggest that the
combination of tivantinib and erlotinib was well tolerated and improved the efﬁcacy of erlotinib for this patient
population, warranting further conﬁrmation from studies with larger patient population.
Image source: The website of the National Cancer
Institute (http://www.cancer.gov)
136 Journal of Thoracic Oncology Vol. 11 No. 22015 AACR-NCI-EORTC International Conference on Molec-
ular Targets and Cancer Therapeutics: AZD9291 Activity in
Patients with Leptomeningeal Disease from Non–Small
Cell Lung Cancer: A Phase I Study (Abstract PR07)
The Phase I BLOOM trial evaluated the use of AZD9291, a
selective third generation EGFR-TKI for sensitizing EGFR
mutations and T790M resistance mutation, in the treat-
ment of leptomeningeal disease from non–small cell lung
cancer (NSCLC). The analysis recruited 13 heavily pre-
treated patients, with EGFR-mutant NSCLC that progressed
on prior EGFR-TKI therapy, who had leptomeningeal dis-
ease conﬁrmed by positive cerebrospinal ﬂuid (CSF)
cytology. Six of the patients were T790M positive. The
longest duration on study treatment for the 11 evaluable
patients was 21 weeks and ongoing. Improvement by im-
aging was observed in 8 patients, and 6 patients reaching a
12-week assessment all showed continued imaging
improvement. Neurological symptom improvement was observed in 5 out of 9 patients. Complete tumor cell
clearance from CSF was seen in 2 patients, and a decrease in EGFR-mutant DNA was found in 7 out of 9 patients, of
which 5 showed >50% decrease. AZD9291 treatment was well tolerated, with adverse events consistent with
those reported in the AURA trial. Treatment termination in 3 patients was as a result of one extracranial pro-
gression, one dysphagia, and one non-drug-related serious adverse event leading to death. The preliminary
ﬁndings suggest efﬁcacy with AZD9291 treatment in heavily pretreated EGFR-mutant NSCLC patients with lep-
tomeningeal disease.Image source: The website of the National Cancer
Institute (http://www.cancer.gov)FDA Approves Necitumumab for Squamous NSCLC
Necitumumab, an anti-EGFR antibody, in combination with
gemcitabine and cisplatin has been approved by the FDA as
the ﬁrst-line treatment for patients with locally advanced or
metastatic squamous non–small cell lung cancer (NSCLC).
The approval was based on the ﬁndings from the phase III
SQUIRE trial demonstrating that the combination improved
overall survival (OS) by 1.6 months (hazard ratio, HR ¼
0.84; P ¼ 0.012), equivalent to a 16% reduction in risk of
death. Progression-free survival (PFS) was improved by
15% with this regimen (HR ¼ 0.85; P ¼ 0.02). The most
common adverse events (AE) of grade 3 or higher in the
combination arm were hypomagnesemia, skin rash, and
venous thromboembolic events. Slightly higher rate of grade
3 AEs and serious AEs were found in the combination arm
(72% vs. 62% and 48% vs. 38%, respectively).
News from the IASLC Tobacco Control Committee
Remarkable Individual Contributions
A report from the Oncology Network (http://oncologynews.com.au/meet-the-melbourne-oncologist-now-at-the-
centre-of-big-tobaccos-dartboard/) tells us the story of Bronwyn King, a radiation oncologist from Melbourne,
Australia who has developed a very important anti-tobacco strategy involving superannuation, at ﬁrst in Australia
and now expanding globally. Several years ago, Dr King realized that her own superannuation involved tobacco
companies and promptly resolved to change this, not only for herself but for her colleagues and for the wider
February 2016 In This Issue 137community. Since then she has driven the divestment of around $1.8 billion Australian dollars worth of tobacco
investment by 33 Australian pension funds and has persuaded the UICC to take this to the international level. In
March 2015, at the 16th World Conference on Tobacco or Health, the UICC launched the Global Task Force for
Tobacco Free Portlfolios (“GTF.TFP” - The tobacco control world has a talent for lengthy acronyms.) that will
develop tobacco divestment strategies world wide. Dr King was dubbed the “$1.3 billion super woman” by the
Sydney Morning Herald last year (http://www.smh.com.au/national/health/meet-the-13-billion-super-woman-how-
dr-king-trumped-big-tobacco-20141203-11zjjx.html) and her work has led to similar tobacco divestment moves in
countries such as New Zealand, Norway, parts of the USA and parts of the UK (https://www.mja.com.au/careers/2
02/1/hitting-big-tobacco-s-hip-pocket).
Dutch pulmonologists Wanda de Kanter and Pauline Dekker, founders of Youth Smoking Prevention
Foundation, can take some credit for shaking up the Dutch government’s interaction with the tobacco in-
dustry. The Foundation challenged the government’s adherence to the principles of Article 5.3 of the
Framework Convention on Tobacco Control (http://ash.org/court-case-against-dutch-state/). If you never
remember another article, or even another Shakespearian quote, remember Article 5.3. Burn it on your
brain. It says,
In setting and implementing their public health policies with respect to tobacco control, Parties shall act to protect
these policies from commercial and other vested interests of the tobacco industry in accordance with national law.
This means that governments should not let tobacco companies push them around. It’s the kind of thing that
makes Philip Morris really, really mad and then take on governments in the courts (as it has done with Australia
over plain packaging, $50 million later and counting). The court in the Hague ruled against the Dutch Foun-
dation over its request that the Dutch government comply with Article 5.3 (the government has reversed de-
cisions on smoking bans in bars and has reduced funding for anti-smoking groups, allegedly because of
inappropriate concessions to tobacco lobbyists), saying that the Foundation is not in a legally robust position
request to ask for for compliance with Article 5.3 (http://www.bbc.com/news/world-europe-16797862).
Despite this loss in court, there has been a win in life. There has been clariﬁcation of the relationship between
the tobacco industry and the Dutch government which has put together a policy document entitled, “Clariﬁ-
cation implementation Article 5.3 WHO Framework Convention” that makes it quite clear how government
should behave in relation to the tobacco industry and, according to Dr de Kanter, “It means that from now on
the doors of government are closed for the tobacco industry and its lobbyists” (http://ash.org/court-case-
against-dutch-state/).
No Kidding
The BBC has produced a documentary uncovering bribery and corruption at the hands of British American Tobacco,
recently shown on television and now available via the BBC online viewer (http://www.bbc.com/news/business-34
964603). According to reports, documents shared by a whistleblower revealed that bribes were paid to FCTC
representatives in Africa and also to undermine anti-tobacco legislation. The investigation continues with the Serious
Fraud Ofﬁce in the UK and could result in huge ﬁnes and prosecution in the UK. The Guardian (http://www.
theguardian.com/business/2015/nov/30/british-american-tobacco-bribing-panorama-smoking) quotes BAT as
disappointed
that the BBC should decide to broadcast allegations made by former employees with a clear vendetta against us, whose
employment was terminated in acrimonious circumstances and who present a completely false picture of the way BAT
does business.
No one is giving BAT much credit however, with calls from the University of Bath’s Tobacco Control Research
Groups (they are behind tobaccotactics.org) and Cancer Research UK for review of potential criminal
offences.
138 Journal of Thoracic Oncology Vol. 11 No. 2Trans-Paciﬁc Partnership Agreement Update
This column loves to talk about the TPPA, the current
embodiment for tobacco control of the best and worst of
worlds. On the one hand, as noted in this column two
months ago, the TPPA explicitly states that, “A Party may
elect to deny the beneﬁts of Investor-State dispute settlement
with respect to a claim challenging a tobacco control measure
of the Party.” Hurray. On the other hand, as noted last
month, the effect of this may be watered down by TPPA
statements that tell us that governments (which may own
Big Tobacco, as is the case in many countries) may have “the
right to challenge each other’s tobacco control measures” and
that many tobacco control measures may not apply to “to-
bacco leaf that is not in the possession of manufacturer,”
whatever that means. An article from the South East Asia Tobacco Control Alliance (seatca.org) published by a
Malaysian news site (https://www.malaysiakini.com/letters/319167#ixzz3rBQ8wfx8) takes us nicely through
the complexities of the TPPA, now that the full text is available (see this column last month). In “TPPA vs tobacco
control – the devil is in the details” we learn that Malaysia, as a signatory to the FCTC, is obliged to reduce tobacco
use and regulate the tobacco industry. According to this report the TPPA encourages corporate social responsibility
(CSR) but the FCTC bans CSR activities by the tobacco industry. Point of confusion, number 1. Another requirement
of the TPPA is that intellectual property issues and ownership of trade secrets conﬂict with the FCTC requirement for
“disclosure to the public [of] information about the toxic constituents of tobacco products..” Point of confusion,
number 2. The article then goes on to describe several more issues where the principles of the TPPA clash with
those of the FCTC and makes the point that a Malaysian proposal for a “carve-out” of tobacco control (http://www.
fctc.org/media-and-publications/fact-sheets/industry-interference/1096-will-malaysia-s-tobacco-carve-out-carry-in-
paciﬁc-trade-deal) was diluted signiﬁcantly by the ﬁnal negotiations. A lot of muddy water obscures the real meaning
of the TPPA for tobacco control; it is clear however that the tobacco control world needs to keep the details in view.
